Neuraxis, INC $NRXS

What the company doesAI summary of filing

Neuraxis, Inc. is a medical technology company that develops neuromodulation devices for chronic gastrointestinal and pain conditions. The company's primary product, IB-Stim, is a percutaneous electrical nerve field stimulation (PENFS) device cleared by the FDA for patients 8 years and older with functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia. The company also markets RED, a rectal expulsion device for evaluating constipation. Neuraxis generates revenue from device sales at $1,195 per device, with patients typically requiring four devices per course of treatment, and sells primarily to children's hospitals, gastroenterology practices, and the Veterans Affairs system. The company is revenue-generating with multiple FDA-cleared products and is conducting additional clinical trials for pipeline indications including post-concussion syndrome, cyclic vomiting syndrome, post-operative pain, and fibromyalgia. [10-K 2026-03-19]

Segments: IB-Stim (PENFS device for functional abdominal pain, functional dyspepsia), RED (Rectal Expulsion Device for constipation evaluation), NSS-2 Bridge (opioid withdrawal, licensed to Masimo until 2025), Pipeline indications (post-concussion syndrome, cyclic vomiting syndrome, post-operative pain, fibromyalgia)